×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Diabetes Market Size

ID: MRFR/Pharma/2180-HCR
60 Pages
Kinjoll Dey
February 2026

India Diabetes Market information, by Type (Type 1, Type 2, and Gestational diabetes), by Test (Random blood sugar test, Fasting blood sugar test, Oral glucose tolerance test, Initial glucose challenge test and others), by Devices (Blood glucose monitoring devices, Diabetes management devices, and others) by Treatment (Medications, Insulin therapy, Transplantation, Bariatric surgery and others) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Diabetes Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Diabetes Size

Diabetes Market Growth Projections and Opportunities

India has a lot of people with diabetes. This changes the market for diabetic products in India in a big way. There is a big market for products and services related to diabetes because a lot of people have it and their lives change all the time. Asia's population is changing, with more middle-class people moving there and people getting older in general. This helps the diabetes market grow. In the diabetes business, the state of India's health care system is a very important thing to talk about. People with diabetes want things and services that help them more when the cost of healthcare facilities, testing services, and treatment choices is high. When the government fights diabetes and makes health rules better for everyone, it has an effect on the market. Indian laws about health care funds, public teaching programs, and ways to keep people from getting diabetes have an effect on the diabetes business. Innovations in health care technology, especially those used to treat diabetes, are a big reason why the market is growing. New medical technologies, like meters that track glucose, systems that give insulin, and digital health solutions, have an effect on business. One important thing that could change how much diabetes patients know and understand. People want better ways to avoid getting diabetes, find out early if they do have it, and get good care. This is what's moving the market for items and services connected to diabetes. Diabetes changes the market because people from different cultures have different health habits and ideas. To get into the market and get people to accept new ways to handle diabetes, you need to know about and deal with the cultural gaps that present. Prices and amounts of income are just two of the economic factors that affect the market. What changes the market are how much people can pay for diabetes care items and services and how many generic drugs are available at fair prices. Drug firms, medical device businesses, and health care providers are competing in India's diabetes industry. Marketers constantly brainstorm fresh, innovative, and affordable concepts to keep ahead of the competition. The area of diabetes is always getting better because new products are being made possible by the research and development that is being done. Companies that spend money on research and development can keep the market growing and adapt to the needs of their customers as they change. In the diabetes market, partnerships between Indian businesses and health care groups from around the world have an impact. When these companies work together, they bring in foreign knowledge, new tools, and money to change the direction of the business.

Diabetes Market Size Graph
Author
Kinjoll Dey
Senior Research Analyst

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Get In Touch

Leave a Comment

FAQs

What is the current valuation of the India Diabetes Market as of 2024?

<p>The India Diabetes Market was valued at 6.86 USD Billion in 2024.</p>

What is the projected market valuation for the India Diabetes Market in 2035?

<p>The market is projected to reach 13.77 USD Billion by 2035.</p>

What is the expected CAGR for the India Diabetes Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the India Diabetes Market during 2025 - 2035 is 6.54%.</p>

Which segments are included in the India Diabetes Market analysis?

<p>The market analysis includes segments such as Type 1, Type 2, Gestational diabetes, Tests, Devices, and Treatment.</p>

What was the market size for Type 2 diabetes in 2024?

<p>The market size for Type 2 diabetes was 4.14 USD Billion in 2024.</p>

How much is the market for blood glucose monitoring devices expected to grow by 2035?

<p>The market for blood glucose monitoring devices is expected to grow from 2.5 USD Billion in 2024 to 5.0 USD Billion by 2035.</p>

What are the key players in the India Diabetes Market?

<p>Key players include Novo Nordisk, Sanofi, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Johnson & Johnson, Abbott Laboratories, Lilly, and AstraZeneca.</p>

What was the valuation for diabetes management devices in 2024?

<p>The valuation for diabetes management devices was 2.0 USD Billion in 2024.</p>

What is the projected market size for fasting blood sugar tests by 2035?

<p>The projected market size for fasting blood sugar tests is expected to reach 3.6 USD Billion by 2035.</p>

How does the market for insulin therapy compare to other treatment segments?

<p>In 2024, the market for insulin therapy was valued at 1.8 USD Billion, indicating a substantial role within the broader treatment segment.</p>

Market Summary

As per MRFR analysis, the Diabetes Market Size was estimated at 6.86 USD Billion in 2024. The Diabetes industry is projected to grow from 7.31 USD Billion in 2025 to 13.77 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.54% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Diabetes Market is experiencing transformative growth driven by technological advancements and increasing awareness.

  • Technological advancements in treatment are reshaping diabetes management strategies across various demographics.
  • The rise of digital health solutions is enhancing patient engagement and self-management capabilities in North America.
  • A focus on preventive care and education is becoming increasingly prevalent, particularly in the Asia-Pacific region.
  • The increasing prevalence of diabetes and advancements in diabetes management technologies are major drivers of market growth.

Market Size & Forecast

2024 Market Size 6.86 (USD Billion)
2035 Market Size 13.77 (USD Billion)
CAGR (2025 - 2035) 6.54%
Largest Regional Market Share in 2024 North America

Major Players

<p>Novo Nordisk (DK), Sanofi (FR), Boehringer Ingelheim (DE), Bristol-Myers Squibb (US), Merck & Co. (US), Johnson & Johnson (US), Abbott Laboratories (US), Eli Lilly and Company (US), AstraZeneca (GB)</p>

Market Trends

The India Diabetes Market is currently experiencing a notable transformation, driven by a combination of rising prevalence of diabetes and increasing awareness regarding the condition. The growing population, coupled with changing lifestyles and dietary habits, appears to contribute significantly to the surge in diabetes cases. As a result, there is a heightened demand for innovative treatment options, including advanced medications and technologies. Healthcare providers are increasingly focusing on personalized care, which may enhance patient outcomes and improve overall management of diabetes. Furthermore, the integration of digital health solutions, such as mobile applications and telemedicine, seems to be reshaping the landscape of diabetes care in India. In addition to treatment advancements, the India Diabetes Market is witnessing a shift towards preventive measures. Public health initiatives aimed at educating the population about diabetes risk factors and promoting healthier lifestyles are gaining traction. This proactive approach may lead to a reduction in the incidence of diabetes over time. Moreover, collaborations between government bodies and private organizations are likely to foster innovation and improve access to diabetes care. Overall, the India Diabetes Market is poised for growth, with a focus on comprehensive management strategies that encompass both treatment and prevention.

Rising Prevalence of Diabetes

The increasing incidence of diabetes in India is a critical factor influencing the market. As more individuals are diagnosed, the demand for effective management solutions is likely to escalate.

Technological Advancements in Treatment

Innovations in diabetes management technologies, such as continuous glucose monitoring systems and insulin delivery devices, are emerging trends. These advancements may enhance patient adherence and improve health outcomes.

Focus on Preventive Healthcare

There is a growing emphasis on preventive measures within the India Diabetes Market. Public health campaigns aimed at educating the population about lifestyle changes could potentially reduce the future burden of diabetes.

Diabetes Market Market Drivers

Growing Geriatric Population

The demographic shift towards an aging population in India is a crucial driver for the India Diabetes Market. As individuals age, the risk of developing diabetes increases, leading to a higher prevalence of the disease among the elderly. Current statistics indicate that approximately 70 million people in India are living with diabetes, with a significant portion being senior citizens. This trend is expected to continue, as the geriatric population is projected to reach 300 million by 2050. Consequently, there is a rising demand for specialized diabetes care products and services tailored to the needs of older adults. This demographic shift presents both challenges and opportunities for healthcare providers and the diabetes market.

Advancements in Diabetes Technology

Technological advancements in diabetes management are transforming the India Diabetes Market. Innovations such as continuous glucose monitoring systems, insulin pumps, and mobile health applications are enhancing the way diabetes is managed. These technologies provide patients with real-time data, enabling better decision-making regarding their health. The market for diabetes technology is expected to witness substantial growth, with projections indicating a compound annual growth rate (CAGR) of over 15% in the coming years. This growth is driven by the increasing adoption of digital health solutions and the demand for personalized diabetes care. As technology continues to evolve, it is likely to improve patient outcomes and streamline diabetes management processes.

Government Initiatives and Policies

Government initiatives aimed at combating diabetes are significantly influencing the India Diabetes Market. Various health policies and programs have been implemented to address the rising diabetes prevalence. For instance, the National Programme for Prevention and Control of Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) aims to reduce the burden of non-communicable diseases through awareness and screening. Such initiatives are likely to enhance access to healthcare services and promote preventive measures. Furthermore, the government is investing in healthcare infrastructure, which is expected to facilitate better diabetes management. This proactive approach may lead to an increase in the availability of diabetes medications and devices, thereby driving market growth.

Increase in Lifestyle-Related Diseases

The rise in lifestyle-related diseases, particularly obesity, is a notable driver in the India Diabetes Market. Sedentary lifestyles, unhealthy dietary habits, and increased stress levels have contributed to a surge in obesity rates, which is closely linked to the development of type 2 diabetes. Recent data suggests that the prevalence of obesity in India has doubled over the past two decades, leading to a corresponding increase in diabetes cases. This alarming trend has prompted healthcare professionals to advocate for lifestyle modifications and preventive measures. As a result, there is a growing market for weight management solutions, dietary supplements, and fitness programs aimed at reducing the risk of diabetes, thereby driving market growth.

Rising Awareness of Diabetes Management

The increasing awareness regarding diabetes management is a pivotal driver in the India Diabetes Market. Educational campaigns and health initiatives have led to a heightened understanding of diabetes, its complications, and the importance of regular monitoring. As a result, more individuals are seeking medical advice and treatment options. This trend is reflected in the growing demand for glucose monitoring devices and insulin products. According to recent estimates, the market for diabetes care devices in India is projected to reach approximately USD 1.5 billion by 2025. This surge in awareness not only encourages early diagnosis but also promotes adherence to treatment regimens, thereby enhancing the overall management of diabetes in the population.

Market Segment Insights

By Type: Type 2 (Largest) vs. Type 1 (Fastest-Growing)

<p>In the India Diabetes Market, Type 2 diabetes holds the largest market share, driven by the increasing prevalence of obesity and sedentary lifestyles. It accounts for approximately 90% of all diabetes cases in India, reflecting the demographic's lifestyle changes and urbanization trends. On the other hand, Type 1 diabetes, though a smaller segment, is witnessing rapid growth due to rising awareness and advancements in insulin therapies, making it a critical focus area for healthcare providers. The growth trends in the diabetes market segments are largely influenced by a combination of lifestyle changes, genetic predisposition, and increasing healthcare access. Type 2 diabetes has a stable growth trend due to its association with obesity, while Type 1 is growing faster, attributed to improved diagnosis and treatment options for younger patients. Furthermore, the rise of gestational diabetes highlights a growing concern among pregnant women, establishing itself as an emerging area of focus for both prevention and management strategies.</p>

<p>Type 2 (Dominant) vs. Type 1 (Emerging)</p>

<p>Type 2 diabetes is the dominant segment in the India Diabetes Market, largely due to its strong correlation with lifestyle factors such as lack of physical activity and poor dietary habits. This type affects a broader demographic, encompassing adults and increasingly, younger populations. In contrast, Type 1 diabetes, characterized by an autoimmune response leading to insulin deficiency, is emerging as a significant area of concern as it predominantly affects children and young adults. The increasing prevalence of Type 1 is prompting more healthcare resources to focus on its management, including innovations in technology and insulin delivery methods. Both segments, while distinct in their characteristics, underline the critical need for targeted diabetes care and public health strategies in India.</p>

By Tests: Fasting Blood Sugar Tests (Largest) vs. Oral Glucose Tolerance Tests (Fastest-Growing)

<p>In the India Diabetes Market, the segment of tests comprises various types that cater to diabetes management and screening. Fasting blood sugar tests hold the largest market share, widely adopted due to their reliability and ease of use. Random blood sugar tests and oral glucose tolerance tests follow closely, addressing specific needs in patient screening and diagnosis. Other tests, while not as prevalent, play a supporting role in the comprehensive assessment of diabetes.</p>

<p>Fasting Blood Sugar Tests (Dominant) vs. Oral Glucose Tolerance Tests (Emerging)</p>

<p>Fasting blood sugar tests are recognized as the dominant testing method for diabetes management in India. These tests provide reliable and accurate readings, making them a first-line choice for healthcare professionals. With increasing awareness and diagnostic capabilities, the adoption of oral glucose tolerance tests is rapidly emerging. These tests are essential for diagnosing gestational diabetes and offer deeper insights into glucose metabolism. As the diabetes prevalence rises, advancements in testing technologies and a focus on early detection are driving growth in both segments, enhancing patient outcomes.</p>

By Devices: Blood Glucose Monitoring Devices (Largest) vs. Diabetes Management Devices (Fastest-Growing)

<p>In the India Diabetes Market, blood glucose monitoring devices are the most significant segment, capturing a substantial market share. These devices are widely used among diabetic patients for regular monitoring of blood sugar levels, which is critical for effective diabetes management. Diabetes management devices, including insulin pumps and continuous glucose monitors, are witnessing rapid growth, reflecting the increasing adoption of advanced technologies among patients. Their share is expanding as more individuals seek integrated solutions for diabetes care. Growth trends in this segment are fueled by the increasing prevalence of diabetes in India, coupled with rising health awareness and access to healthcare. The push for digital health solutions is driving innovation within diabetes management devices, resulting in sophisticated devices that offer better accuracy and usability. Moreover, government initiatives to improve diabetes care and management are enhancing market prospects, creating a favorable environment for rapid growth in this segment.</p>

<p>Blood Glucose Monitoring Devices (Dominant) vs. Diabetes Management Devices (Emerging)</p>

<p>Blood glucose monitoring devices have established themselves as the dominant category in the India Diabetes Market, characterized by their essential role in diabetes management. These devices, which include traditional glucometers and more advanced continuous glucose monitoring systems, are crucial for providing real-time insights into blood sugar levels. The increasing awareness among patients about the necessity of regular monitoring has solidified their position. On the other hand, diabetes management devices are emerging as an important asset for comprehensive diabetes care. This category includes innovative technologies that facilitate insulin delivery and continuous glucose tracking, appealing to a tech-savvy patient base that demands efficiency and convenience. As healthcare evolves in India, both these segments are set to play vital roles, with monitoring devices leading the way while management devices rapidly gain traction.</p>

By Treatment: Insulin Therapy (Largest) vs. Medications (Fastest-Growing)

<p>In the India Diabetes Market, the treatment segment is diverse, with significant contributions from various solutions. Insulin therapy holds the largest market share due to its long-established role in managing diabetes, particularly for Type 1 diabetes patients and those with advanced Type 2 diabetes. This segment benefits from healthcare providers' accessibility and adherence to treatment protocols, which reinforces insulin's importance in diabetes management. On the other hand, the medications segment is experiencing rapid growth as newer oral and injectable medications emerge, catering to the diverse needs of patients and promoting better glycemic control. The growth trends for diabetes treatments in India are influenced by increasing diabetes prevalence, enhanced healthcare infrastructure, and advancements in technology. The demand for medications is rising due to their availability in various forms, including combination therapies, making them attractive for patients seeking alternatives to insulin. Additionally, the heightened awareness of diabetes complications and prevention strategies are driving investments in insulin therapy, while innovative oral medications are providing effective solutions for emerging diabetes patients, encouraging a shift towards pharmaceutical treatments that offer improved accessibility and lifestyle integration.</p>

<p>Insulin Therapy (Dominant) vs. Medications (Emerging)</p>

<p>Insulin therapy remains the dominant treatment option in the India Diabetes Market, primarily due to its established efficacy in controlling blood glucose levels and its critical role for patients with severe diabetes. This treatment is backed by a well-regulated supply chain and widespread acceptance among healthcare professionals, ensuring that insulin remains a cornerstone in diabetes management. Conversely, medications are emerging as a popular alternative, particularly with the introduction of newer drugs that are revolutionizing diabetes care. These medications often offer benefits like oral administration and fewer side effects, attracting patients who are reluctant to use needles and are seeking a more convenient management solution. This duality in treatment options signifies a shift towards personalization in diabetes management, responding to varying patient preferences and requirements.</p>

By Market Channel: Retail Pharmacies (Largest) vs. Online Pharmacies (Fastest-Growing)

<p>In the diabetes market, Retail Pharmacies hold the largest market share among the various market channels. They provide essential diabetes management products ranging from insulin to glucose monitoring devices, offering a wide selection and immediacy that customers value. In contrast, Online Pharmacies are quickly capturing market share, driven by the convenience of home delivery and the growing trend of e-commerce. This shift is particularly relevant in urban areas where access to physical stores may be limited. Growth trends within the market channel segment are propelled by increased awareness of diabetes management options and technological advancements. The rise of telehealth services and digital wellness platforms is making it easier for patients to obtain their medications and support. Online Pharmacies, in particular, are benefiting from this change, with consumers seeking more convenient purchasing options, making them the fastest-growing segment in the diabetes market.</p>

<p>Retail Pharmacies (Dominant) vs. Online Pharmacies (Emerging)</p>

<p>Retail Pharmacies represent the dominant force in the diabetes market, serving as the primary access point for most patients requiring diabetes supplies and medications. Their established infrastructure allows for immediate medication access, ensuring patients can manage their conditions with ease. On the other hand, Online Pharmacies have emerged as a significant player, appealing to a tech-savvy demographic that prioritizes convenience and discretion in their healthcare purchases. They provide an array of products for diabetes management while often offering competitive pricing and home delivery services. As consumer preferences shift towards more digital solutions, Online Pharmacies are positioned to grow rapidly, establishing themselves as a viable alternative to traditional pharmacy services.</p>

Get more detailed insights about India Diabetes Market Research Report - Forecast To 2035

Regional Insights

North America : Healthcare Innovation Leader

The North American diabetes market is driven by advanced healthcare infrastructure, increasing prevalence of diabetes, and innovative treatment options. The U.S. holds the largest market share at approximately 70%, followed by Canada at around 15%. Regulatory support for new drug approvals and reimbursement policies further catalyze market growth. The rising awareness of diabetes management and preventive care is also a significant demand driver. Leading countries in this region include the United States and Canada, with major players like Novo Nordisk, Sanofi, and Merck & Co. dominating the landscape. The competitive environment is characterized by continuous innovation and partnerships among pharmaceutical companies. The presence of advanced research facilities and a focus on personalized medicine are key factors enhancing market dynamics.

Europe : Diverse Market Dynamics

The European diabetes market is characterized by diverse healthcare systems and varying regulatory frameworks across countries. Germany and France are the largest markets, holding approximately 25% and 20% market shares, respectively. The European Medicines Agency (EMA) plays a crucial role in facilitating drug approvals, which supports market expansion. Increasing healthcare expenditure and a growing aging population are significant growth drivers in this region. Key players such as AstraZeneca, Sanofi, and Boehringer Ingelheim are actively involved in the European market. The competitive landscape is marked by a focus on innovative therapies and biosimilars. Countries like the UK and Italy are also emerging as important markets, driven by rising diabetes prevalence and enhanced patient access to treatment options.

Asia-Pacific : Emerging Market Potential

The Asia-Pacific diabetes market is witnessing rapid growth due to increasing urbanization, lifestyle changes, and rising obesity rates. India and China are the largest markets, accounting for approximately 30% and 25% of the market share, respectively. Government initiatives aimed at improving healthcare access and diabetes awareness are significant catalysts for market growth. The region's diverse population and varying healthcare systems present both challenges and opportunities for market players. India is emerging as a key player in the diabetes market, with major companies like Abbott Laboratories and Johnson & Johnson expanding their presence. The competitive landscape is evolving, with a focus on affordable treatment options and innovative technologies. The increasing prevalence of diabetes in urban areas is driving demand for effective management solutions, making this region a focal point for future investments.

Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa diabetes market is characterized by a growing prevalence of diabetes, driven by lifestyle changes and urbanization. Countries like South Africa and the UAE are leading the market, holding approximately 20% and 15% market shares, respectively. Government initiatives aimed at improving healthcare infrastructure and diabetes awareness are crucial for market growth. The region's diverse economic landscape presents both challenges and opportunities for market players. Key players such as Merck & Co. and Lilly are increasingly focusing on this region, recognizing the potential for growth. The competitive landscape is marked by a mix of multinational corporations and local companies. The rising demand for diabetes management solutions is prompting investments in healthcare facilities and innovative treatment options, making this region an emerging market for diabetes care.

Key Players and Competitive Insights

The India Diabetes Market is characterized by a rapidly evolving competitive landscape, driven by increasing prevalence rates and a growing demand for innovative treatment solutions. Major players such as Novo Nordisk (DK), Sanofi (FR), and Abbott Laboratories (US) are strategically positioned to leverage their extensive portfolios and research capabilities. Novo Nordisk (DK) focuses on innovation in insulin delivery systems, while Sanofi (FR) emphasizes partnerships with local healthcare providers to enhance patient access. Abbott Laboratories (US) is investing heavily in digital health solutions, indicating a shift towards integrated care models. Collectively, these strategies not only enhance their market presence but also contribute to a more competitive environment that prioritizes patient-centric solutions.

Key business tactics employed by these companies include localizing manufacturing and optimizing supply chains to meet the unique demands of the Indian market. The competitive structure of the diabetes market in India appears moderately fragmented, with several players vying for market share. However, the influence of key players is substantial, as they set benchmarks for quality and innovation, thereby shaping the overall market dynamics.

In August 2025, Sanofi (FR) announced a strategic partnership with a leading Indian telehealth platform to enhance diabetes management through remote monitoring. This collaboration is significant as it aligns with the growing trend of digital health solutions, enabling better patient engagement and adherence to treatment protocols. Such initiatives are likely to improve health outcomes and solidify Sanofi's position in the market.

In September 2025, Abbott Laboratories (US) launched a new continuous glucose monitoring system tailored for the Indian population, which is expected to revolutionize diabetes management. This product introduction not only showcases Abbott's commitment to innovation but also addresses the specific needs of Indian patients, potentially increasing their market share. The strategic importance of this launch lies in its ability to provide real-time data, thereby empowering patients and healthcare providers alike.

In October 2025, Novo Nordisk (DK) expanded its manufacturing capabilities in India by investing in a new facility aimed at producing biosimilars. This move is indicative of the company's long-term strategy to enhance local production and reduce dependency on imports. The establishment of this facility is likely to improve supply chain reliability and reduce costs, positioning Novo Nordisk favorably against competitors.

As of October 2025, current competitive trends in the India Diabetes Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances, such as those between pharmaceutical companies and technology firms, are shaping the landscape by fostering innovation and improving patient outcomes. Looking ahead, competitive differentiation is expected to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, thereby enhancing the overall quality of care in diabetes management.

Key Companies in the Diabetes Market include

Industry Developments

February 2024:In February 2024, Roche Diabetes Market Care Launched a new continuous glucose monitoring (CGM) system in India, aiming to improve diabetes management and glycemic control.

Study objectives of India Diabetes Market

  • To provide detailed analysis of the market structure along with forecast for the next 6 years of the various segments and sub-segments of the Indian Diabetes Market
  • To provide insights about factors affecting the market growth
  • To analyze the India Diabetes Market based on various factors - price analysis, supply chain analysis, Porters Five Forces analysis etc.
  • To provide historical and forecast revenue of the market segments and sub-segments
  • To provide detailed analysis of the market with respect to the current market size and future prospective
  • To provide detailed analysis of the market for segments by type, by test, by devices, by treatment, and its sub-segments.
  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Market

 Intended Audience

  • Hospitals and Clinics
  • Diabetes Market drugs and devices manufacturers
  • Diabetes Market drugs and devices suppliers
  • Government and Independent Regulatory Authorities
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Medical Research Laboratories
  • Potential Investors

Future Outlook

Diabetes Market Future Outlook

The India Diabetes Market is projected to grow at a 6.54% CAGR from 2024 to 2035, driven by increasing prevalence, technological advancements, and rising healthcare expenditure.

New opportunities lie in:

  • Development of personalized diabetes management apps
  • Expansion of telehealth services for diabetes care
  • Investment in AI-driven predictive analytics for patient monitoring

By 2035, the India Diabetes Market is expected to be robust, driven by innovation and increased healthcare access.

Market Segmentation

Diabetes Market Type Outlook

  • Type 1
  • Type 2
  • Gestational diabetes

Diabetes Market Tests Outlook

  • Random blood sugar tests
  • Fasting blood sugar tests
  • Oral glucose tolerance tests
  • Initial glucose challenge tests
  • Others

Diabetes Market Devices Outlook

  • Blood glucose monitoring devices
  • Diabetes management devices
  • Others

Diabetes Market Treatment Outlook

  • Medications
  • Insulin therapy
  • Transplantation
  • Bariatric surgery
  • Blood Sugar Treatment

Report Scope

MARKET SIZE 20246.86(USD Billion)
MARKET SIZE 20257.309(USD Billion)
MARKET SIZE 203513.77(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)6.54% (2024 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Billion
Key Companies ProfiledMarket analysis in progress
Segments CoveredMarket segmentation analysis in progress
Key Market OpportunitiesIntegration of digital health solutions enhances diabetes management in the India Diabetes Market.
Key Market DynamicsRising prevalence of diabetes drives demand for innovative treatment solutions and enhanced patient care in India.
Countries CoveredNorth America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the India Diabetes Market as of 2024?

<p>The India Diabetes Market was valued at 6.86 USD Billion in 2024.</p>

What is the projected market valuation for the India Diabetes Market in 2035?

<p>The market is projected to reach 13.77 USD Billion by 2035.</p>

What is the expected CAGR for the India Diabetes Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the India Diabetes Market during 2025 - 2035 is 6.54%.</p>

Which segments are included in the India Diabetes Market analysis?

<p>The market analysis includes segments such as Type 1, Type 2, Gestational diabetes, Tests, Devices, and Treatment.</p>

What was the market size for Type 2 diabetes in 2024?

<p>The market size for Type 2 diabetes was 4.14 USD Billion in 2024.</p>

How much is the market for blood glucose monitoring devices expected to grow by 2035?

<p>The market for blood glucose monitoring devices is expected to grow from 2.5 USD Billion in 2024 to 5.0 USD Billion by 2035.</p>

What are the key players in the India Diabetes Market?

<p>Key players include Novo Nordisk, Sanofi, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Johnson & Johnson, Abbott Laboratories, Lilly, and AstraZeneca.</p>

What was the valuation for diabetes management devices in 2024?

<p>The valuation for diabetes management devices was 2.0 USD Billion in 2024.</p>

What is the projected market size for fasting blood sugar tests by 2035?

<p>The projected market size for fasting blood sugar tests is expected to reach 3.6 USD Billion by 2035.</p>

How does the market for insulin therapy compare to other treatment segments?

<p>In 2024, the market for insulin therapy was valued at 1.8 USD Billion, indicating a substantial role within the broader treatment segment.</p>

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Type of Diabetes (USD Billion)
    2. | | 4.1.1 Type 1 Diabetes
    3. | | 4.1.2 Type 2 Diabetes
    4. | | 4.1.3 Gestational Diabetes
    5. | | 4.1.4 LADA
    6. | | 4.1.5 MODY
    7. | 4.2 Healthcare, BY Treatment Method (USD Billion)
    8. | | 4.2.1 Insulin Therapy
    9. | | 4.2.2 Oral Medications
    10. | | 4.2.3 Dietary Management
    11. | | 4.2.4 Continuous Glucose Monitoring
    12. | | 4.2.5 Exercise Regimens
    13. | 4.3 Healthcare, BY Patient Demographics (USD Billion)
    14. | | 4.3.1 Children
    15. | | 4.3.2 Adults
    16. | | 4.3.3 Elderly
    17. | | 4.3.4 Pregnant Women
    18. | | 4.3.5 Obese Individuals
    19. | 4.4 Healthcare, BY Complications (USD Billion)
    20. | | 4.4.1 Cardiovascular Disease
    21. | | 4.4.2 Neuropathy
    22. | | 4.4.3 Retinopathy
    23. | | 4.4.4 Kidney Disease
    24. | | 4.4.5 Foot Problems
    25. | 4.5 Healthcare, BY Market Channel (USD Billion)
    26. | | 4.5.1 Retail Pharmacies
    27. | | 4.5.2 Online Pharmacies
    28. | | 4.5.3 Hospitals
    29. | | 4.5.4 Clinics
    30. | | 4.5.5 Diabetes Care Centers
    31. | 4.6 Healthcare, BY Region (USD Billion)
    32. | | 4.6.1 North America
    33. | | | 4.6.1.1 US
    34. | | | 4.6.1.2 Canada
    35. | | 4.6.2 Europe
    36. | | | 4.6.2.1 Germany
    37. | | | 4.6.2.2 UK
    38. | | | 4.6.2.3 France
    39. | | | 4.6.2.4 Russia
    40. | | | 4.6.2.5 Italy
    41. | | | 4.6.2.6 Spain
    42. | | | 4.6.2.7 Rest of Europe
    43. | | 4.6.3 APAC
    44. | | | 4.6.3.1 China
    45. | | | 4.6.3.2 India
    46. | | | 4.6.3.3 Japan
    47. | | | 4.6.3.4 South Korea
    48. | | | 4.6.3.5 Malaysia
    49. | | | 4.6.3.6 Thailand
    50. | | | 4.6.3.7 Indonesia
    51. | | | 4.6.3.8 Rest of APAC
    52. | | 4.6.4 South America
    53. | | | 4.6.4.1 Brazil
    54. | | | 4.6.4.2 Mexico
    55. | | | 4.6.4.3 Argentina
    56. | | | 4.6.4.4 Rest of South America
    57. | | 4.6.5 MEA
    58. | | | 4.6.5.1 GCC Countries
    59. | | | 4.6.5.2 South Africa
    60. | | | 4.6.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Novo Nordisk (DK)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Sanofi (FR)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Boehringer Ingelheim (DE)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Merck & Co. (US)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 AbbVie (US)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Eli Lilly and Company (US)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Johnson & Johnson (US)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 AstraZeneca (GB)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 Roche (CH)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY TYPE OF DIABETES
    4. | 6.4 US MARKET ANALYSIS BY TREATMENT METHOD
    5. | 6.5 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    6. | 6.6 US MARKET ANALYSIS BY COMPLICATIONS
    7. | 6.7 US MARKET ANALYSIS BY MARKET CHANNEL
    8. | 6.8 CANADA MARKET ANALYSIS BY TYPE OF DIABETES
    9. | 6.9 CANADA MARKET ANALYSIS BY TREATMENT METHOD
    10. | 6.10 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    11. | 6.11 CANADA MARKET ANALYSIS BY COMPLICATIONS
    12. | 6.12 CANADA MARKET ANALYSIS BY MARKET CHANNEL
    13. | 6.13 EUROPE MARKET ANALYSIS
    14. | 6.14 GERMANY MARKET ANALYSIS BY TYPE OF DIABETES
    15. | 6.15 GERMANY MARKET ANALYSIS BY TREATMENT METHOD
    16. | 6.16 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    17. | 6.17 GERMANY MARKET ANALYSIS BY COMPLICATIONS
    18. | 6.18 GERMANY MARKET ANALYSIS BY MARKET CHANNEL
    19. | 6.19 UK MARKET ANALYSIS BY TYPE OF DIABETES
    20. | 6.20 UK MARKET ANALYSIS BY TREATMENT METHOD
    21. | 6.21 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    22. | 6.22 UK MARKET ANALYSIS BY COMPLICATIONS
    23. | 6.23 UK MARKET ANALYSIS BY MARKET CHANNEL
    24. | 6.24 FRANCE MARKET ANALYSIS BY TYPE OF DIABETES
    25. | 6.25 FRANCE MARKET ANALYSIS BY TREATMENT METHOD
    26. | 6.26 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    27. | 6.27 FRANCE MARKET ANALYSIS BY COMPLICATIONS
    28. | 6.28 FRANCE MARKET ANALYSIS BY MARKET CHANNEL
    29. | 6.29 RUSSIA MARKET ANALYSIS BY TYPE OF DIABETES
    30. | 6.30 RUSSIA MARKET ANALYSIS BY TREATMENT METHOD
    31. | 6.31 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    32. | 6.32 RUSSIA MARKET ANALYSIS BY COMPLICATIONS
    33. | 6.33 RUSSIA MARKET ANALYSIS BY MARKET CHANNEL
    34. | 6.34 ITALY MARKET ANALYSIS BY TYPE OF DIABETES
    35. | 6.35 ITALY MARKET ANALYSIS BY TREATMENT METHOD
    36. | 6.36 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    37. | 6.37 ITALY MARKET ANALYSIS BY COMPLICATIONS
    38. | 6.38 ITALY MARKET ANALYSIS BY MARKET CHANNEL
    39. | 6.39 SPAIN MARKET ANALYSIS BY TYPE OF DIABETES
    40. | 6.40 SPAIN MARKET ANALYSIS BY TREATMENT METHOD
    41. | 6.41 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    42. | 6.42 SPAIN MARKET ANALYSIS BY COMPLICATIONS
    43. | 6.43 SPAIN MARKET ANALYSIS BY MARKET CHANNEL
    44. | 6.44 REST OF EUROPE MARKET ANALYSIS BY TYPE OF DIABETES
    45. | 6.45 REST OF EUROPE MARKET ANALYSIS BY TREATMENT METHOD
    46. | 6.46 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    47. | 6.47 REST OF EUROPE MARKET ANALYSIS BY COMPLICATIONS
    48. | 6.48 REST OF EUROPE MARKET ANALYSIS BY MARKET CHANNEL
    49. | 6.49 APAC MARKET ANALYSIS
    50. | 6.50 CHINA MARKET ANALYSIS BY TYPE OF DIABETES
    51. | 6.51 CHINA MARKET ANALYSIS BY TREATMENT METHOD
    52. | 6.52 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    53. | 6.53 CHINA MARKET ANALYSIS BY COMPLICATIONS
    54. | 6.54 CHINA MARKET ANALYSIS BY MARKET CHANNEL
    55. | 6.55 INDIA MARKET ANALYSIS BY TYPE OF DIABETES
    56. | 6.56 INDIA MARKET ANALYSIS BY TREATMENT METHOD
    57. | 6.57 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    58. | 6.58 INDIA MARKET ANALYSIS BY COMPLICATIONS
    59. | 6.59 INDIA MARKET ANALYSIS BY MARKET CHANNEL
    60. | 6.60 JAPAN MARKET ANALYSIS BY TYPE OF DIABETES
    61. | 6.61 JAPAN MARKET ANALYSIS BY TREATMENT METHOD
    62. | 6.62 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    63. | 6.63 JAPAN MARKET ANALYSIS BY COMPLICATIONS
    64. | 6.64 JAPAN MARKET ANALYSIS BY MARKET CHANNEL
    65. | 6.65 SOUTH KOREA MARKET ANALYSIS BY TYPE OF DIABETES
    66. | 6.66 SOUTH KOREA MARKET ANALYSIS BY TREATMENT METHOD
    67. | 6.67 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    68. | 6.68 SOUTH KOREA MARKET ANALYSIS BY COMPLICATIONS
    69. | 6.69 SOUTH KOREA MARKET ANALYSIS BY MARKET CHANNEL
    70. | 6.70 MALAYSIA MARKET ANALYSIS BY TYPE OF DIABETES
    71. | 6.71 MALAYSIA MARKET ANALYSIS BY TREATMENT METHOD
    72. | 6.72 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    73. | 6.73 MALAYSIA MARKET ANALYSIS BY COMPLICATIONS
    74. | 6.74 MALAYSIA MARKET ANALYSIS BY MARKET CHANNEL
    75. | 6.75 THAILAND MARKET ANALYSIS BY TYPE OF DIABETES
    76. | 6.76 THAILAND MARKET ANALYSIS BY TREATMENT METHOD
    77. | 6.77 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    78. | 6.78 THAILAND MARKET ANALYSIS BY COMPLICATIONS
    79. | 6.79 THAILAND MARKET ANALYSIS BY MARKET CHANNEL
    80. | 6.80 INDONESIA MARKET ANALYSIS BY TYPE OF DIABETES
    81. | 6.81 INDONESIA MARKET ANALYSIS BY TREATMENT METHOD
    82. | 6.82 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    83. | 6.83 INDONESIA MARKET ANALYSIS BY COMPLICATIONS
    84. | 6.84 INDONESIA MARKET ANALYSIS BY MARKET CHANNEL
    85. | 6.85 REST OF APAC MARKET ANALYSIS BY TYPE OF DIABETES
    86. | 6.86 REST OF APAC MARKET ANALYSIS BY TREATMENT METHOD
    87. | 6.87 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    88. | 6.88 REST OF APAC MARKET ANALYSIS BY COMPLICATIONS
    89. | 6.89 REST OF APAC MARKET ANALYSIS BY MARKET CHANNEL
    90. | 6.90 SOUTH AMERICA MARKET ANALYSIS
    91. | 6.91 BRAZIL MARKET ANALYSIS BY TYPE OF DIABETES
    92. | 6.92 BRAZIL MARKET ANALYSIS BY TREATMENT METHOD
    93. | 6.93 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    94. | 6.94 BRAZIL MARKET ANALYSIS BY COMPLICATIONS
    95. | 6.95 BRAZIL MARKET ANALYSIS BY MARKET CHANNEL
    96. | 6.96 MEXICO MARKET ANALYSIS BY TYPE OF DIABETES
    97. | 6.97 MEXICO MARKET ANALYSIS BY TREATMENT METHOD
    98. | 6.98 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    99. | 6.99 MEXICO MARKET ANALYSIS BY COMPLICATIONS
    100. | 6.100 MEXICO MARKET ANALYSIS BY MARKET CHANNEL
    101. | 6.101 ARGENTINA MARKET ANALYSIS BY TYPE OF DIABETES
    102. | 6.102 ARGENTINA MARKET ANALYSIS BY TREATMENT METHOD
    103. | 6.103 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    104. | 6.104 ARGENTINA MARKET ANALYSIS BY COMPLICATIONS
    105. | 6.105 ARGENTINA MARKET ANALYSIS BY MARKET CHANNEL
    106. | 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF DIABETES
    107. | 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT METHOD
    108. | 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    109. | 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY COMPLICATIONS
    110. | 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY MARKET CHANNEL
    111. | 6.111 MEA MARKET ANALYSIS
    112. | 6.112 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF DIABETES
    113. | 6.113 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT METHOD
    114. | 6.114 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    115. | 6.115 GCC COUNTRIES MARKET ANALYSIS BY COMPLICATIONS
    116. | 6.116 GCC COUNTRIES MARKET ANALYSIS BY MARKET CHANNEL
    117. | 6.117 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF DIABETES
    118. | 6.118 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT METHOD
    119. | 6.119 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    120. | 6.120 SOUTH AFRICA MARKET ANALYSIS BY COMPLICATIONS
    121. | 6.121 SOUTH AFRICA MARKET ANALYSIS BY MARKET CHANNEL
    122. | 6.122 REST OF MEA MARKET ANALYSIS BY TYPE OF DIABETES
    123. | 6.123 REST OF MEA MARKET ANALYSIS BY TREATMENT METHOD
    124. | 6.124 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    125. | 6.125 REST OF MEA MARKET ANALYSIS BY COMPLICATIONS
    126. | 6.126 REST OF MEA MARKET ANALYSIS BY MARKET CHANNEL
    127. | 6.127 KEY BUYING CRITERIA OF HEALTHCARE
    128. | 6.128 RESEARCH PROCESS OF MRFR
    129. | 6.129 DRO ANALYSIS OF HEALTHCARE
    130. | 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    131. | 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    132. | 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
    133. | 6.133 HEALTHCARE, BY TYPE OF DIABETES, 2024 (% SHARE)
    134. | 6.134 HEALTHCARE, BY TYPE OF DIABETES, 2024 TO 2035 (USD Billion)
    135. | 6.135 HEALTHCARE, BY TREATMENT METHOD, 2024 (% SHARE)
    136. | 6.136 HEALTHCARE, BY TREATMENT METHOD, 2024 TO 2035 (USD Billion)
    137. | 6.137 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    138. | 6.138 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
    139. | 6.139 HEALTHCARE, BY COMPLICATIONS, 2024 (% SHARE)
    140. | 6.140 HEALTHCARE, BY COMPLICATIONS, 2024 TO 2035 (USD Billion)
    141. | 6.141 HEALTHCARE, BY MARKET CHANNEL, 2024 (% SHARE)
    142. | 6.142 HEALTHCARE, BY MARKET CHANNEL, 2024 TO 2035 (USD Billion)
    143. | 6.143 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    5. | | 7.2.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    6. | | 7.2.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    7. | | 7.2.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    8. | | 7.2.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    9. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    10. | | 7.3.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    11. | | 7.3.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    12. | | 7.3.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    13. | | 7.3.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    14. | | 7.3.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    15. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    16. | | 7.4.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    17. | | 7.4.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    18. | | 7.4.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    19. | | 7.4.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    20. | | 7.4.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    21. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    22. | | 7.5.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    23. | | 7.5.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    24. | | 7.5.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    25. | | 7.5.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    26. | | 7.5.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    27. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    28. | | 7.6.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    29. | | 7.6.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    30. | | 7.6.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    31. | | 7.6.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    32. | | 7.6.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    33. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    34. | | 7.7.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    35. | | 7.7.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    36. | | 7.7.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    37. | | 7.7.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    38. | | 7.7.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    39. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    40. | | 7.8.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    41. | | 7.8.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    42. | | 7.8.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    43. | | 7.8.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    44. | | 7.8.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    45. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    46. | | 7.9.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    47. | | 7.9.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    48. | | 7.9.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    49. | | 7.9.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    50. | | 7.9.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    51. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    52. | | 7.10.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    53. | | 7.10.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    54. | | 7.10.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    55. | | 7.10.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    56. | | 7.10.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    57. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    58. | | 7.11.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    59. | | 7.11.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    60. | | 7.11.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    61. | | 7.11.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    62. | | 7.11.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    63. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.12.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    65. | | 7.12.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    66. | | 7.12.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    67. | | 7.12.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    68. | | 7.12.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    69. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    70. | | 7.13.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    71. | | 7.13.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    72. | | 7.13.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    73. | | 7.13.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    74. | | 7.13.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    75. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    76. | | 7.14.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    77. | | 7.14.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    78. | | 7.14.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    79. | | 7.14.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    80. | | 7.14.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    81. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    82. | | 7.15.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    83. | | 7.15.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    84. | | 7.15.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    85. | | 7.15.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    86. | | 7.15.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    87. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    88. | | 7.16.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    89. | | 7.16.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    90. | | 7.16.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    91. | | 7.16.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    92. | | 7.16.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    93. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    94. | | 7.17.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    95. | | 7.17.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    96. | | 7.17.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    97. | | 7.17.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    98. | | 7.17.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    99. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    100. | | 7.18.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    101. | | 7.18.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    102. | | 7.18.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    103. | | 7.18.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    104. | | 7.18.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    105. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    106. | | 7.19.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    107. | | 7.19.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    108. | | 7.19.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    109. | | 7.19.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    110. | | 7.19.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    111. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    112. | | 7.20.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    113. | | 7.20.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    114. | | 7.20.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    115. | | 7.20.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    116. | | 7.20.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    117. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    118. | | 7.21.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    119. | | 7.21.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    120. | | 7.21.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    121. | | 7.21.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    122. | | 7.21.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    123. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    124. | | 7.22.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    125. | | 7.22.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    126. | | 7.22.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    127. | | 7.22.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    128. | | 7.22.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    129. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    130. | | 7.23.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    131. | | 7.23.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    132. | | 7.23.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    133. | | 7.23.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    134. | | 7.23.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    135. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    136. | | 7.24.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    137. | | 7.24.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    138. | | 7.24.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    139. | | 7.24.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    140. | | 7.24.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    141. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    142. | | 7.25.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    143. | | 7.25.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    144. | | 7.25.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    145. | | 7.25.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    146. | | 7.25.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    147. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    148. | | 7.26.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    149. | | 7.26.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    150. | | 7.26.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    151. | | 7.26.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    152. | | 7.26.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    153. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    154. | | 7.27.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    155. | | 7.27.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    156. | | 7.27.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    157. | | 7.27.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    158. | | 7.27.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    159. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    160. | | 7.28.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    161. | | 7.28.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    162. | | 7.28.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    163. | | 7.28.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    164. | | 7.28.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    165. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    166. | | 7.29.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    167. | | 7.29.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    168. | | 7.29.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    169. | | 7.29.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    170. | | 7.29.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    171. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    172. | | 7.30.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion)
    173. | | 7.30.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
    174. | | 7.30.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    175. | | 7.30.4 BY COMPLICATIONS, 2025-2035 (USD Billion)
    176. | | 7.30.5 BY MARKET CHANNEL, 2025-2035 (USD Billion)
    177. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    178. | | 7.31.1
    179. | 7.32 ACQUISITION/PARTNERSHIP
    180. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Type of Diabetes (USD Billion, 2025-2035)

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
  • LADA
  • MODY

Healthcare By Treatment Method (USD Billion, 2025-2035)

  • Insulin Therapy
  • Oral Medications
  • Dietary Management
  • Continuous Glucose Monitoring
  • Exercise Regimens

Healthcare By Patient Demographics (USD Billion, 2025-2035)

  • Children
  • Adults
  • Elderly
  • Pregnant Women
  • Obese Individuals

Healthcare By Complications (USD Billion, 2025-2035)

  • Cardiovascular Disease
  • Neuropathy
  • Retinopathy
  • Kidney Disease
  • Foot Problems

Healthcare By Market Channel (USD Billion, 2025-2035)

  • Retail Pharmacies
  • Online Pharmacies
  • Hospitals
  • Clinics
  • Diabetes Care Centers
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓